Literature DB >> 15322165

Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod.

Francesca Palamara1, Simone Meindl, Martin Holcmann, Petra Lührs, Georg Stingl, Maria Sibilia.   

Abstract

Among the different subsets of dendritic cells (DC) described in humans and mice, epidermal Langerhans cells and dermal DCs represent the only DC populations resident in normal skin. In this study we describe a population of CD4(+)CD3(-) plasmacytoid DC (pDC)-like cells that accumulate in the dermis and spleens of mice topically treated with imiquimod, a low m.w. immune response modifier with potent antiviral and antitumor activities. These CD4(+)CD3(-) cells coexpress GR-1, B220, MHC class II, and, to a lesser extent, CD11c and display the phenotypic features of pDCs described in lymphoid organs. The accumulation of pDC-like cells after imiquimod treatment was detected not only in normal skin, but also in intradermally induced melanomas. Imiquimod treatment leads either to complete regression or to a significant reduction of the tumors. The number of pDCs correlates well with the clinical response of the tumors to the drug, suggesting that the antitumor effects of imiquimod could be mediated at least in part by the recruitment of pDC-like cells to the skin. Therefore, strategies aimed at activating and directing these cells into neoplastic tissues may be a promising and novel approach for the immunotherapy of various types of cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15322165     DOI: 10.4049/jimmunol.173.5.3051

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  54 in total

1.  CCR6/CCR10-mediated plasmacytoid dendritic cell recruitment to inflamed epithelia after instruction in lymphoid tissues.

Authors:  Vanja Sisirak; Nelly Vey; Béatrice Vanbervliet; Thomas Duhen; Isabelle Puisieux; Bernhard Homey; Edward P Bowman; Giorgio Trinchieri; Bertrand Dubois; Dominique Kaiserlian; Sergio A Lira; Alain Puisieux; Jean-Yves Blay; Christophe Caux; Nathalie Bendriss-Vermare
Journal:  Blood       Date:  2011-09-21       Impact factor: 22.113

Review 2.  Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases.

Authors:  M Afshar; A D Martinez; R L Gallo; T R Hata
Journal:  J Eur Acad Dermatol Venereol       Date:  2012-06-01       Impact factor: 6.166

3.  Toll-like receptor-7 ligand Imiquimod induces type I interferon and antimicrobial peptides to ameliorate dextran sodium sulfate-induced acute colitis.

Authors:  Satheesh K Sainathan; Kumar S Bishnupuri; Konrad Aden; Qizhi Luo; Courtney W Houchen; Shrikant Anant; Brian K Dieckgraefe
Journal:  Inflamm Bowel Dis       Date:  2011-09-26       Impact factor: 5.325

Review 4.  Plasmacytoid dendritic cells: in search of their niche in immune responses.

Authors:  Winfried Barchet; Amanda Blasius; Marina Cella; Marco Colonna
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

5.  Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse.

Authors:  Nadira Durakovic; Vedran Radojcic; Mario Skarica; Karl B Bezak; Jonathan D Powell; Ephraim J Fuchs; Leo Luznik
Journal:  Blood       Date:  2007-01-16       Impact factor: 22.113

6.  Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream.

Authors:  Abel Torres; Leslie Storey; Makala Anders; Richard L Miller; Barbara J Bulbulian; Jizhong Jin; Shalini Raghavan; James Lee; Herbert B Slade; Woubalem Birmachu
Journal:  J Transl Med       Date:  2007-01-26       Impact factor: 5.531

7.  Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization.

Authors:  Caroline Aspord; Laetitia Tramcourt; Claire Leloup; Jean-Paul Molens; Marie-Therese Leccia; Julie Charles; Joel Plumas
Journal:  J Invest Dermatol       Date:  2014-04-21       Impact factor: 8.551

8.  Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity.

Authors:  Ingunn M Stromnes; J Scott Brockenbrough; Kamel Izeradjene; Markus A Carlson; Carlos Cuevas; Randi M Simmons; Philip D Greenberg; Sunil R Hingorani
Journal:  Gut       Date:  2014-02-20       Impact factor: 23.059

9.  Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant.

Authors:  Sylvia Adams; David W O'Neill; Daisuke Nonaka; Elizabeth Hardin; Luis Chiriboga; Kimberly Siu; Crystal M Cruz; Angelica Angiulli; Francesca Angiulli; Erika Ritter; Rose Marie Holman; Richard L Shapiro; Russell S Berman; Natalie Berner; Yongzhao Shao; Olivier Manches; Linda Pan; Ralph R Venhaus; Eric W Hoffman; Achim Jungbluth; Sacha Gnjatic; Lloyd Old; Anna C Pavlick; Nina Bhardwaj
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

10.  Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin.

Authors:  Susan J Huang; Dirkjan Hijnen; George F Murphy; Thomas S Kupper; Adam W Calarese; Ilse G Mollet; Carl F Schanbacher; Danielle M Miller; Chrysalyne D Schmults; Rachael A Clark
Journal:  J Invest Dermatol       Date:  2009-06-11       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.